SCN2A and epilepsy: Though GS967 has been shown to be an efficacious antiepileptic in rodent models of SCN1A, SCN2A, and SCN8A epilepsies [63,64,65,66], the safety, tolerability, and antiepileptic efficacy of GS967/Prax330 in human patients with refractory epilepsy remains to be fully investigated.